Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 4, 2006

Primary Completion Date

October 4, 2017

Study Completion Date

October 4, 2017

Conditions
Myelofibrosis
Interventions
DRUG

Busulfan

Test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days

DRUG

Fludarabine

40 mg/m\^2 by vein daily over 1 hour x 4 days

DRUG

Thymoglobulin (ATG)

2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00475020 - Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter